期刊文献+

自身抗体检测在系统性红斑狼疮合并难治性血小板减少患者病情评估中的价值 被引量:7

Value of autoantibody detection for illness assessment in systemic lupus erythematosus patients with refractory thrombocytopenia
下载PDF
导出
摘要 目的:分析自身抗体检测在系统性红斑狼疮(SLE)合并难治性血小板减少患者病情评估中的价值。方法:60例SLE合并难治性血小板减少患者作为观察组A,58例单纯SLE患者为观察组B,66例接受体检的健康人作为对照组。抽取研究对象的外周循环血并检测自身抗体、病情相关因子及Th17、Th1、Th2细胞因子和补体等水平,进一步分析SLE伴难治性血小板减少患者特征性抗体阳性率与病情严重程度的相关关系。结果:观察组A抗RNP抗体、抗Sm抗体、抗Scl-70抗体、抗AnuA抗体、抗His抗体、抗双链DNA(ds-DNA)抗体阳性率均高于观察组B及对照组(P<0.05);观察组A可溶性细胞间黏附分子-1(sICAM-1)、血浆血栓调节蛋白(PTM)、可溶性CD30配体(sCD30L)、单核细胞趋化蛋白1(MCP-1)值高于观察组B及对照组(P<0.05);观察组A血清白介素(IL)-17、IL-23、干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)、IL-4、IL-5、IL-6值均高于观察组B及对照组(P<0.05);观察组A血清C1qAg、C3、C4、补体因子(CFH)值低于观察组B及对照组,C1qAb值高于观察组B及对照组(P<0.05);SLE患者的抗Sm抗体及抗ds-DNA抗体阳性率与血清sICAM-1、PTM、sCD30L、MCP-1、IL-17、IL-23、IFN-γ、TNF-α、IL-4、IL-5、IL-6、C1qAb值呈正比,与C1qAg、C3、C4、CFH值呈反比(P<0.05)。结论:系统性红斑狼疮合并难治性血小板减少患者的自身特异性抗体阳性率高,且与患者病情严重程度存在直接相关关系,可作为远期临床治疗指导、预后判断的可靠指标。 Objective:To analyze the value of autoantibody detection for illness assessment in systemic lupus erythematosus patients with refractory thrombocytopenia.Methods:A total of 60 cases of systemic lupus erythematosus(SLE)patients with refractory thrombocytopenia were the observation group A,58 cases of patients with SLE alone were the observation group B,and 66 cases of healthy people who received physical examination were control group.Peripheral circulating blood was drawn from research subjects to detect the levels of autoantibody,illness-related factors,Th17,Th1 and Th2cytokines,complements,and so on,and then the correlation between specific antibody positive rate and disease severity in SLE patients with refractory thrombocytopenia was further analyzed.Results:Anti-RNP antibody,anti-Sm antibody,anti-Scl-70 antibody,anti-AnuA antibody,anti-His antibody and anti-ds-DNA antibody positive rates of observation group A were significantly higher than those of observation group B and control group(P〈0.05);soluble intercellular cell adhesion molecule(sICAM-1),plasma thrombomodulin(PTM),sCD30 Land motocyte chemoattractant protein-1(MCP-1)values of observation group A were significantly higher than those of observation group B and control group(P〈0.05);serum interleukin(IL)-17,IL-23,IFN-γ,tumor necrosis factor-α(TNF-α),IL-4,IL-5and IL-6values of observation group A were significantly higher than those of observation group B and control group(P〈0.05);serum C1 qAg,C3,C4 and complement factor H(CFH)values of observation group A were lower than those of observation group B and control group while C1 qAb value was significantly higher than that of observation group B and control group(P〈0.05);anti-Sm antibody and anti-ds-DNA antibody positive rates of SLE patients were positively correlated with serum sICAM-1,PTM,sCD30 L,MCP-1,IL-17,IL-23,interferon-γ(IFN-γ),TNF-α,IL-4,IL-5,IL-6and C1 qAb values,and negatively correlated with C1 qAg,C3,C4 and CFH values(P〈0.05).Conclusions:Specific autoantibody positive rates are high in systemic lupus erythematosus patients with refractory thrombocytopenia,have direct correlation with the disease severity and can be used as the reliable indexes of long-term clinical treatment guidance and prognosis judgment.
作者 吴晓亮
出处 《海南医学院学报》 CAS 2016年第13期1414-1417,1421,共5页 Journal of Hainan Medical University
基金 2014年度广东省医学科研基金立项课题(A2014548)~~
关键词 系统性红斑狼疮(SLE) 难治性血小板减少 自身抗体检测 Systemic lupus erythematosus Refractory thrombocytopenia Autoantibody detection
  • 相关文献

参考文献16

  • 1Tamaddoni A,Yousefghahari B,Khani A,et al.Isolated thrombocytopenia;A report of a rare presentation of childhood systemic lupus erythematosus(SLE)[J].Caspian J Intern Med,2015,6(3):174-176.
  • 2Lu C,Nossent J.Thrombopoietin levels in systemic lupus erythematosus are linked to inflammatory cytokines,but unrelated to thrombocytopenia or thrombosis[J].Lupus,2015,24(1):18-24.
  • 3Khellaf M,Chabrol A,Mahevas M,et al.Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies[J].Am J Hematol,2014,89(2):194-198.
  • 4邢桂芝,石哲群,褚金龙,房成,张雅青.自身抗体检测对系统性红斑狼疮的诊断价值分析[J].中国实验诊断学,2014,18(8):1321-1323. 被引量:6
  • 5Jovancevic B,Lindholm C,Pullerits R.Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients:long-term follow-up and review of the literature[J].Lupus,2013,22(7):664-674.
  • 6Jucaud V,Ravindranath MH,Terasaki PI,et al.Serum antibodies to human leucocyte antigen(HLA)-E,HLA-F and HLA-G in patients with systemic lupus erythematosus(SLE)during disease flares:Clinical relevance of HLA-F autoantibodies[J].Clin Exp Immunol,2016,183(3):326-340.
  • 7陈华,苏金梅,王迁,吴庆军,费允云,王立,郑文洁,张烜,曾小峰,张奉春.小剂量利妥昔单抗治疗系统性红斑狼疮或干燥综合征合并血小板减少症:长期随访研究[J].中华临床免疫和变态反应杂志,2013,7(2):139-145. 被引量:10
  • 8Jiang B,Li T,Guo L,et al.Efficacy and safety of rituximab in systemic lupus erythematosus and sjgren syndrome patients with refractory thrombocytopenia:A retrospective study of 21cases[J].J Clin Rheumatol,2015,21(5):244-250.
  • 9Nause SL,Spiegler J,Weichert J,et al.Therapeutic management of evans syndrome in a pregnancy with maternal systemic lupus erythematosus[J].Z Geburtshilfe Neonatol,2015,219(4):190-192.
  • 10Jeon JY,Kim KY,Kim BS,et al.FcγRIIB gene polymorphisms are associated with disease risk and clinical manifestations ofsystemic lupus erythematosus in koreans[J].Tohoku J Exp Med,2015,236(3):185-191.

二级参考文献45

  • 1Maloney DG,Grillo-Lopez AJ,White CA,et al.IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin' s Lymphoma[J].Blood,1997,90:2188-2195.
  • 2Emery P,Fleischmann R,Filipowicz-Sosnowska A,et al.The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment:results of a phase IIB randomized,double-blind,placebo-controlled,dose-ranging trial[J].Arthritis Rheum,2006,54:1390-1400.
  • 3Garcia-Chavez J,Majluf-Cruz A,Montiel-Cervantes L,et al.Rituximab therapy for chronic and refractory immune thrombocytopenic purpura:a long-term follow-up analysis[J].Ann Hematol,2007,86:871-877.
  • 4Zaja F,Battista ML,Pirrotta MT,et al.Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura[J].Haematologica,2008,93:930-933.
  • 5Zaja F,Vianelli N,Volpetti S,et al.Low-dose rituximab in adult patients with primary immune thrombocytopenia[J].Eur J Haematol,2010,85:329-334.
  • 6Galarza-Maldonado C,Kourilovitch MR,Molineros JE,et al.The administration of low doses of rituximab followed by hydroxychloroquine,prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus[J].Autoimmun Rev,2010,10:108-111.
  • 7Jónsdóttir T,Gunnarsson I,Risselada A,et al.Treatment of refractory SLE with rituximab plus cyclophosphamide:clinical effects,serological changes,and predictors of response[J].Ann Rheum Dis,2008,67:330-334.
  • 8Looney RJ,Anolik JH,Campbell D,et al.B cell depletion as a novel treatment for systemic lupus erythematosus:a phase I/II dose-escalation trial of rituximab[J].Arthritis Rheum,2004,50:2580-2589.
  • 9Sanz I,Lee FE-H.B cells as therapeutic targets in SLE[J].Nat Rev Rheumatol,2010,6:326-337.
  • 10Smith KGC,Jones RB,Burns SM,et al.Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis:Remission,relapse,and re-treatment[J].Arthritis Rheum,2006,54:2970-2982.

共引文献25

同被引文献61

引证文献7

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部